Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
Bioavailability: Overview01:17

Bioavailability: Overview

Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing transdermal drug delivery using translational data and mechanistic based modeling.

Drug delivery and translational research·2026
Same author

Characterization of Peptide-Preservative Interaction by AlphaFold, Molecular Dynamics Simulation, and NMR Spectroscopy.

Molecular pharmaceutics·2025
Same author

The Impact of Permeation Enhancers on Transcellular Permeation of Small Molecule Drugs.

The journal of physical chemistry. B·2025
Same author

Plant Cell Wall Polysaccharide <i>O</i>-Acetyltransferases.

Plants (Basel, Switzerland)·2024
Same author

Identification of glycosyltransferases mediating 2-O-arabinopyranosyl and 2-O-galactosyl substitutions of glucuronosyl side chains of xylan.

The Plant journal : for cell and molecular biology·2024
Same author

A rice GT61 glycosyltransferase possesses dual activities mediating 2-O-xylosyl and 2-O-arabinosyl substitutions of xylan.

Planta·2024
Same journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same journal

In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug.

The AAPS journal·2026
Same journal

Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles.

The AAPS journal·2026
Same journal

Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation.

The AAPS journal·2026
Same journal

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same journal

Correction: Nanotechnology-enhanced Natural Products for Cancer Chemoprevention: Molecular Mechanisms and Clinical Translation.

The AAPS journal·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Effective absorption modeling in relative bioavailability study risk assessment.

John P Rose1

  • 1Pharmaceutical Sciences Research and Development, Eli Lilly & Company, 1223 W. Morris St. Lilly Technology Center, Indianapolis, Indiana 46221, USA. Rose_John_P@lilly.com

The AAPS Journal
|September 12, 2012
PubMed
Summary
This summary is machine-generated.

Absorption modeling aids risk assessment for relative bioavailability (RBA) studies by predicting drug absorption differences. A framework is presented to enhance modeling reliability for informed RBA decisions.

Related Experiment Videos

Last Updated: May 18, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Pharmaceutical Sciences
  • Regulatory Science

Background:

  • Absorption modeling offers strategic advantages for risk assessment in relative bioavailability (RBA) studies.
  • A key challenge in using absorption modeling for risk assessment is managing inherent uncertainties.
  • Effective application necessitates understanding when modeling is reliable and how to build reliability into the process.

Purpose of the Study:

  • To present a framework for effective absorption modeling in RBA risk assessment.
  • To enhance the reliability and confidence in absorption modeling for regulatory decision-making.
  • To guide the integration of absorption modeling into the RBA study decision process.

Main Methods:

  • Developed a framework based on four fundamental building blocks for reliable absorption modeling.
  • Related drug product change severity and API properties to model reliability.
  • Utilized critical model variables to define drug product differences and generated response surfaces for performance evaluation.
  • Emphasized good model building practices to ensure high-quality models.

Main Results:

  • The proposed framework integrates drug product characteristics with modeling reliability for RBA risk assessment.
  • Demonstrated the framework's application using a common example of a solid-state change (free base to HCl salt).
  • The framework provides a structured approach to evaluate the likelihood of significant differences in drug absorption.

Conclusions:

  • Absorption modeling, when reliably built, is a valuable tool for RBA risk assessment.
  • The framework enhances the strategic use of absorption modeling by addressing uncertainty and building confidence.
  • This approach supports informed decisions regarding the necessity of RBA studies, optimizing drug development processes.